Loading…
Loading…
BIO-B does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BIO-B and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIO-B and 80,000+ other tickers.
See exactly how BIO-B's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIO-B and 80,000+ other tickers.
Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America. The company's business is organized into two main divisions: Life Science and Clinical Diagnostics. The Life Science division develops and provides a comprehensive array of reagents, laboratory apparatus, and instruments. These are vital for various applications, including scientific research methodologies, biopharmaceutical production…
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.
Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.
Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.
Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.